title: [Complications of successively double autologous hemopoietic stem cell transplants].
abstract: In order to get clinical information about safety and feasibility of successively double autologous hemopoietic stem cell transplants (SD-AHSCT) in malignant hematological disease patients, the complications and hematological reconstitution after SD-AHSCT in 20 patients were analyzed retrospectively. 20 patients with hematologic malignancies received autologous peripheral blood stem/progenitor cell transplantation at the first transplant, and then were given autologous bone marrow transplantation as the second transplant at 4-10 months. The results showed that all the patients tolerated mobilization and collection of peripheral blood stem/progenitor cells as well as bone marrow collection. All the patients got enough hematological stem/progenitor cells for SD-AHSCT and achieved hematological reconstitution after SD-AHSCT. The speed of hematological reconstitution was positively correlated with the transfused quantity of hematological stem/progenitor cells (r = 0.968). The hematological reconstitution after the first autologous hemopoietic stem cell transplant (AHSCT) was earlier than that of the second (P < 0.05). There was no statistical difference between the first and the second AHSCT for the incidence of skin or mucous membrane bleeding (P > 0.05). No patients occurred massive hemorrhage during SD-AHSCT. The quantity of platelet transfusion in the second AHSCT was larger than that in the first AHSCT (P < 0.01). The incidence of oral ulcer in the first AHSCT was significantly higher than that in the second (P < 0.01). No statistical difference between the first and the second AHSCT was there in infectious sites, infectious pathogens and infection incidence (P > 0.10). All the complications were improved or cured, and no patients died of SD-AHSCT complications. In conclusion, SD-AHSCT is safe and feasible, and worthy to be further popularized.
authors.affiliation: Department of Hematology, General Hospital of PLA, Beijing 100853, China.
authors.forename: Wen-Rong
authors.initials: WR
authors.lastname: Huang
authors.forename: Wan-Ming
authors.initials: WM
authors.lastname: Da
authors.forename: Bo-Long
authors.initials: BL
authors.lastname: Zhang
authors.forename: Chun-Ji
authors.initials: CJ
authors.lastname: Gao
authors.forename: Xiao-Ping
authors.initials: XP
authors.lastname: Han
authors.forename: Yu
authors.initials: Y
authors.lastname: Jing
authors.forename: Xiao-Xiong
authors.initials: XX
authors.lastname: Wu
authors.forename: Yu
authors.initials: Y
authors.lastname: Zhao
authors.forename: Hong-Hua
authors.initials: HH
authors.lastname: Li
authors.forename: Quan-Shun
authors.initials: QS
authors.lastname: Wang
authors.forename: Yi-Zhuo
authors.initials: YZ
authors.lastname: Zhang
authors.forename: Jian
authors.initials: J
authors.lastname: Bo
mesh_terms: D000293:Adolescent; D000328:Adult; D005260:Female; D019337:Hematologic Neoplasms / Q000601:surgery*; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects / Q000379:methods*; D006801:Humans; D008297:Male; D019226:Oral Ulcer / Q000209:etiology; D036102:Peripheral Blood Stem Cell Transplantation / Q000009:adverse effects / Q000379:methods*; D017713:Platelet Transfusion / Q000706:statistics & numerical data; D015203:Reproducibility of Results; D012189:Retrospective Studies; D014182:Transplantation, Autologous